# Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis

> **NCT01143337** · PHASE2 · COMPLETED · sponsor: **Tanabe Pharma Corporation** · enrollment: 112 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** MP-435(dose1) + Methotrexate
- **DRUG:** Placebo + Methotrexate

## Key facts

- **NCT ID:** NCT01143337
- **Lead sponsor:** Tanabe Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2012-03
- **Final completion:** 2012-03
- **Target enrollment:** 112 (ACTUAL)
- **Last updated:** 2026-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143337

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143337, "Efficacy and Safety Study of MP-435 in Combination With Methotrexate (MTX) in Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-07-12 from https://api.ai-analytics.org/clinical/NCT01143337. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*